

Rolf C R Ljung

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9096032/publications.pdf>

Version: 2024-02-01

66
papers

2,997
citations

201385

27
h-index

161609

54
g-index

71
all docs

71
docs citations

71
times ranked

1814
citing authors

#	ARTICLE	IF	CITATIONS
1	Factor VIII Products and Inhibitor Development in Severe Hemophilia A. <i>New England Journal of Medicine</i> , 2013, 368, 231-239.	13.9	383
2	Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. <i>Blood</i> , 2013, 121, 4046-4055.	0.6	287
3	Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. <i>British Journal of Haematology</i> , 1999, 105, 1109-1113.	1.2	258
4	Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s. <i>Blood</i> , 2013, 122, 1129-1136.	0.6	200
5	Factor IX Inhibitors and Anaphylaxis in Hemophilia B. <i>The American Journal of Pediatric Hematology/Oncology</i> , 1997, 19, 23-27.	1.3	168
6	Intracranial haemorrhage in haemophilia A and B. <i>British Journal of Haematology</i> , 2008, 140, 378-384.	1.2	162
7	Somatic Mosaicism in Hemophilia A: A Fairly Common Event. <i>American Journal of Human Genetics</i> , 2001, 69, 75-87.	2.6	144
8	Practical aspects of extended half-life products for the treatment of haemophilia. <i>Therapeutic Advances in Hematology</i> , 2018, 9, 295-308.	1.1	85
9	Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients. <i>European Journal of Haematology</i> , 2019, 102, 111-122.	1.1	78
10	Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A. <i>Blood</i> , 2019, 134, 317-320.	0.6	71
11	Haemophilia B mutations in Sweden: a population-based study of mutational heterogeneity. <i>British Journal of Haematology</i> , 2001, 113, 81-86.	1.2	68
12	Pain and pain management in haemophilia. <i>Blood Coagulation and Fibrinolysis</i> , 2016, 27, 845-854.	0.5	66
13	Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study. <i>Haematologica</i> , 2020, 106, 123-129.	1.7	60
14	Correlation between phenotype and genotype in a large unselected cohort of children with severe hemophilia A. <i>Blood</i> , 2013, 121, 3946-3952.	0.6	59
15	Intracranial haemorrhage in children and adolescents with severe haemophilia A or B – the impact of prophylactic treatment. <i>British Journal of Haematology</i> , 2017, 179, 298-307.	1.2	56
16	The current status of prophylactic replacement therapy in children and adults with haemophilia. <i>British Journal of Haematology</i> , 2015, 169, 777-786.	1.2	52
17	Immune tolerance induction in patients with severe hemophilia with inhibitors: expert panel views and recommendations for clinical practice. <i>European Journal of Haematology</i> , 2012, 88, 371-379.	1.1	50
18	Can haemophilic arthropathy be prevented?. <i>British Journal of Haematology</i> , 1998, 101, 215-219.	1.2	49

#	ARTICLE	IF	CITATIONS
19	Prophylactic therapy in haemophilia. <i>Blood Reviews</i> , 2009, 23, 267-274.	2.8	49
20	The risk associated with indwelling catheters in children with haemophilia. <i>British Journal of Haematology</i> , 2007, 138, 580-586.	1.2	48
21	Increased burden on caregivers of having a child with haemophilia complicated by inhibitors. <i>Pediatric Blood and Cancer</i> , 2014, 61, 706-711.	0.8	41
22	Haemophilia B: Where are we now and what does the future hold?. <i>Blood Reviews</i> , 2018, 32, 52-60.	2.8	41
23	Origin of mutation in sporadic cases of haemophilia A. <i>British Journal of Haematology</i> , 1999, 106, 870-874.	1.2	40
24	How I manage patients with inherited haemophilia A and B and factor inhibitors. <i>British Journal of Haematology</i> , 2018, 180, 501-510.	1.2	36
25	Mode of delivery in hemophilia: vaginal delivery and Cesarean section carry similar risks for intracranial hemorrhages and other major bleeds. <i>Haematologica</i> , 2019, 104, 2100-2106.	1.7	30
26	Primary prophylaxis in haemophilia care: Guideline update 2016. <i>Blood Cells, Molecules, and Diseases</i> , 2017, 67, 81-85.	0.6	29
27	Aspects of prophylactic treatment of hemophilia. <i>Thrombosis Journal</i> , 2016, 14, 30.	0.9	28
28	Bleeding before prophylaxis in severe hemophilia: paradigm shift over two decades. <i>Haematologica</i> , 2015, 100, e84-e86.	1.7	27
29	Practical considerations in choosing a factor VIII prophylaxis regimen: Role of clinical phenotype and trough levels. <i>Thrombosis and Haemostasis</i> , 2016, 115, 913-920.	1.8	27
30	Central venous catheters in children with haemophilia. <i>Blood Reviews</i> , 2004, 18, 93-100.	2.8	24
31	Hemophilia and prophylaxis. <i>Pediatric Blood and Cancer</i> , 2013, 60, S23-6.	0.8	21
32	Origin of mutation in sporadic cases of haemophiliaâ€B. <i>European Journal of Haematology</i> , 1992, 48, 142-145.	1.1	19
33	Moderate haemophilia B in a female carrier caused by preferential inactivation of the paternal X chromosome. <i>European Journal of Haematology</i> , 1991, 47, 257-261.	1.1	18
34	Genetic Counseling of Hemophilia Carriers. <i>Seminars in Thrombosis and Hemostasis</i> , 2003, 29, 031-036.	1.5	17
35	How to manage invasive procedures in children with haemophilia. <i>British Journal of Haematology</i> , 2012, 157, 519-528.	1.2	17
36	Sports participation and physical activity in adult Dutch and Swedish patients with severe haemophilia: A comparison between intermediateâ€and highâ€dose prophylaxis. <i>Haemophilia</i> , 2019, 25, 244-251.	1.0	16

#	ARTICLE	IF	CITATIONS
37	Haplotype Analysis of Identical Factor IX Mutants Using PCR. <i>Thrombosis and Haemostasis</i> , 1992, 67, 066-069.	1.8	16
38	Practical considerations for nonfactorâ€ replacement therapies in the treatment of haemophilia with inhibitors. <i>Haemophilia</i> , 2021, 27, 340-350.	1.0	15
39	Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2274-2282.	1.8	13
40	Prevention and Management of Bleeding Episodes in Children with Hemophilia. <i>Paediatric Drugs</i> , 2018, 20, 455-464.	1.3	13
41	Principles of care for acquired hemophilia. <i>European Journal of Haematology</i> , 2021, 106, 762-773.	1.1	11
42	Genetic Variants of Haemophilia B Detected by Immunoradiometric Assay: Implications for Prenatal Diagnosis. <i>Pediatric Research</i> , 1982, 16, 256-258.	1.1	10
43	Inversions of the factor VIII gene in Swedish patients with severe haemophilia A. <i>European Journal of Haematology</i> , 1995, 54, 310-313.	1.1	10
44	Joint disease, the hallmark of haemophilia: What issues and challenges remain despite the development of effective therapies?. <i>Thrombosis Research</i> , 2014, 133, 967-971.	0.8	10
45	Outcome measures for adult and pediatric hemophilia patients with inhibitors. <i>European Journal of Haematology</i> , 2017, 99, 103-111.	1.1	8
46	Various regimens for prophylactic treatment of patients with haemophilia. <i>European Journal of Haematology</i> , 2015, 94, 11-16.	1.1	7
47	Inheritable Molecular Variants of Moderate and Mild Hemophilia A. <i>Acta Medica Scandinavica</i> , 1981, 209, 11-16.	0.0	6
48	Genetic screening of children with suspected inherited bleeding disorders. <i>Haemophilia</i> , 2020, 26, 314-324.	1.0	6
49	Beyond stopping the bleed: short-term episodic prophylaxis with recombinant activated factor FVII in haemophilia patients with inhibitors. <i>Blood Transfusion</i> , 2017, 15, 77-84.	0.3	6
50	Targeted re-sequencing of F8, F9 and VWF: Characterization of Ion Torrent data and clinical implications for mutation screening. <i>PLoS ONE</i> , 2019, 14, e0216179.	1.1	5
51	Detection of F8 int2h inversions using digital droplet PCR and mileâ€ post assays. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1039-1049.	1.9	4
52	IMMUNORADIOMETRIC ASSAY OF INHIBITORS OF ANTIHAEMOPHILIC FACTOR A. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 1982, 71, 1019-1023.	0.7	3
53	Haemoglobin KÃ¶ln as <i>de novo</i> mutations in Sweden: Diagnosis by PCR and specific enzymatic cleavage. <i>European Journal of Haematology</i> , 1994, 52, 156-161.	1.1	3
54	Registries and databasesâ€ A European perspective. <i>Haemophilia</i> , 2020, 26, 26-28.	1.0	3

#	ARTICLE	IF	CITATIONS
55	The Fourth Annual Meeting of the International Network for Pediatric Hemophilia: Current Challenges and Recommendations in the Clinical Care of Children with Hemophilia. <i>Transfusion Medicine and Hemotherapy</i> , 2010, 37, 209-212.	0.7	2
56	Detection of mosaics in hemophilia A by deep Ion Torrent sequencing and droplet digital PCR. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 1121-1130.	1.0	2
57	Continued benefit demonstrated with BAY 81-8973 prophylaxis in previously treated children with severe haemophilia A: Interim analysis from the LEOPOLD Kids extension study. <i>Thrombosis Research</i> , 2020, 189, 96-101.	0.8	2
58	Droplet digital PCR and mileâ€post analysis for the detection of F8 int.1h inversions. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 732-737.	1.9	2
59	Genetic Diagnosis of Hemophilia A. <i>Pediatric Hematology and Oncology</i> , 1994, 11, 9-11.	0.3	1
60	Can a â€center effectâ€ explain the higher frequency of inhibitors for a second-generation recombinant factor VIII product?. <i>Blood</i> , 2015, 126, 2164-2165.	0.6	1
61	The care of a child with a newly diagnosed immune thrombocytopenia. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2017, 106, 1554-1555.	0.7	1
62	Silent variant in <i>F8</i> :c.222G>T (p.Thr74Thr) causes a partial exon skipping in a patient with mild hemophilia A. <i>Molecular Genetics & Genomic Medicine</i> , 2022, 10, e1856.	0.6	1
63	Studies of chronic ITP in children and adolescents. <i>Pediatric Blood and Cancer</i> , 2006, 47, 660-661.	0.8	0
64	Identification of <i>F8</i> rearrangements in carrier and nonâ€carrier mothers of haemophilia A patients. <i>Haemophilia</i> , 2021, 27, e654-e658.	1.0	0
65	Pulmonary Embolism in Children with Asymptomatic Proximal Deep Vein Thromboembolism: Single-Center Experience from Sweden. <i>Blood</i> , 2020, 136, 4-4.	0.6	0
66	Predicting Thrombosis Recurrence in Children: The Role of Thrombophilia Testing. <i>Blood</i> , 2020, 136, 2-3.	0.6	0